Johnson & Johnson

Latest Headlines

Latest Headlines

Pharma giants join forces on $285M antibiotics collaboration

GlaxoSmithKline, Sanofi, AstraZeneca, J&J as well as Basilea will join an R&D consortium including Europe's Innovative Medicines Initiative to fund the effort, setting up an information hub that will share data among investigators laboring on new antibiotics.

J&J loses key FDA panel vote on Xarelto

The balloting turned against J&J after 6 of 10 outside experts concluded that the risk of bleeding and doubts about its pivotal data prevented them from endorsing an approval for preventing heart attacks and strokes among patients with heart problems.

NICE nod for Xarelto as FDA panel mulls new use

The advisory panel is weighing evidence for a new, potentially lucrative use in patients with acute coronary syndrome.

Chinese court favors J&J in distribution fight

Johnson & Johnson ($JNJ) has won a lawsuit against a long-time distribution partner in China. While the amount of money involved may seem puny, it appears to be a big victory in a country that is terribly protective of its domestic drug distributors.

FDA staff backs J&J's Xarelto for heart condition

The staffers' recommendation of approval comes ahead of Wednesday's advisory committee meeting on the expanded use of J&J and Bayer's Xarelto in ACS patients.

How does pharma's CEO pay rank?

We know how pharma CEO pay stacked up within the industry. But how did pharma's 2011 compensation packages compare with those in other industries?

FDA review backs Xarelto for big new use in ACS patients

The anticoagulant won a thumbs-up from FDA reviewers ahead of Wednesday's advisory panel meeting, where FDA experts will weigh a lucrative new indication.

Johnson & Johnson recalls a lot of Imodium

Johnson & Johnson's McNeil Consumer Healthcare is retrieving a lot of Imodium--nearly 54,000 packages

J&J's Zytiga may be useful in early prostate cancer, too

A new study suggests Zytiga may be effective in early-stage disease. The small trial--it involved only 58 patients with localized, high-risk cancer--found that Zytiga wiped out or nearly wiped out tumors in one-third of them.

Pennsylvania still trying get a slice of J&J Risperdal payouts

PA alleges that J&J oversold the drug's benefits while underselling the risks.